Fresenius Medical Care

What Fresenius Medical Care does

Fresenius Medical Care is the world's largest provider of dialysis products and services, operating ~3,539 clinics across multiple continents and serving ~290,000 patients directly, with a reach that touches an estimated ~4.5 million dialysis patients globally. The company is headquartered in Bad Homburg, Germany, is listed on the Frankfurt Stock Exchange (FME) and NYSE (FMS), and operates as a publicly traded subsidiary of Fresenius SE & Co. KGaA. Its footprint combines direct clinical care delivery with the manufacture and sale of the equipment, consumables, and software used in that care.

The core technology stack spans in-center hemodialysis machines (5008X CAREsystem, 6008, 4008 series), FX-series dialyzers, critical care devices (multiFiltratePRO), home dialysis systems (NxStage), and the kinexus connected health platform launched globally in June 2026 for home dialysis management. The Renal Research Institute provides the data and clinical research foundation, and the Nephronomics JV extends into AI-driven kidney disease drug discovery using a 42,000-patient consented dataset.

The business model operates two interlocking revenue streams. First, dialysis services revenue is generated from per-treatment reimbursement across ~290,000 clinic patients, primarily paid by government programs such as U.S. Medicare/Medicaid and equivalent European single-payer systems. Second, dialysis products revenue is generated from sales of machines, dialyzers, bloodlines, and consumables to both the company's own clinic network and third-party providers. The FME25+ transformation program targets €804 million in sustainable cost savings to fund reinvestment in value-based care via the InterWell Health acquisition and digital expansion via kinexus.

Name

Fresenius Medical Care

Legal name

Fresenius Medical Care AG

Website

https://freseniusmedicalcare.com

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Fresenius Medical Care is the world's largest dialysis provider, operating ~3,539 clinics and serving ~290,000 patients globally while manufacturing dialysis machines, dialyzers, and connected health software for the kidney care market.

Ownership category

akta.pro rank

Product category

Dialysis Services

NAICS

Kidney Dialysis Centers (621492), Ambulatory Health Care Services (621), Offices of Physicians (62111)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Outpatient Dialysis & Kidney Care Centers (HLAFABAE)

akta.pro secondary industries

Dialysis Services (Hemodialysis & Peritoneal Dialysis) (HLAKAHAC), Dialyzers (Artificial Kidneys) (HLAHAKAC), Peritoneal Dialysis (PD) Systems & Supplies (HLAHAKAB), Home Dialysis Equipment & Remote Monitoring (HLAHAKAG), Dialysis Water Treatment & Dialysate Delivery Systems (HLAHAKAD), Home Dialysis Support & Training Providers (HLAFAEAG)

Keywords

• Dialysis services
• Hemodialysis machines
• Kidney replacement therapy
• Dialyzers and filters
• Renal care products

Headquarters

HQ city

Bad Homburg

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Dialysis Services: Revenue from operating a network of approximately 3,539 dialysis clinics globally, providing in-center and home dialysis treatments. Reimbursed primarily through government programs (Medicare, Medicaid) and private insurers. Represents the largest portion of revenue with recurring treatment-based billing.
2. Dialysis Products (Devices, Disposables, Dialyzers): Sale of proprietary dialysis machines, dialyzers (FX series), critical care disposables, peritoneal dialysis fluids, and water treatment systems. Sold directly to healthcare facilities and through the company's own clinic network.
3. Value-Based Care / Interwell Health: Interwell Health, the value-based care operating segment, generates revenue through shared savings arrangements with the CMS Kidney Care Choices Model. Delivered $273 million in shared savings to CMS over three years.
4. FreseniusRx (Kidney Pharmacy Services): Specialized kidney pharmacy services providing medications to dialysis patients, with studies showing reduced mortality and hospitalizations for patients using the specialized pharmacy program versus retail pharmacies.
5. Digital Health Platform (kinexus): Cloud-based digital platform supporting home dialysis programs, potentially generating software/subscription revenue from therapy management, remote monitoring, and supply ordering features.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Fresenius Medical Care is the world's largest provider of dialysis products and services, operating approximately 3,539-3,600 dialysis clinics globally that deliver in-center and home dialysis treatments to approximately 290,000 patients. The company manufactures and sells proprietary dialysis machines (5008X, 6008, 5008S CorDiax, NxStage), dialyzers, acute blood purification systems, peritoneal dialysis fluids, and water treatment solutions directly to healthcare providers, while also delivering value-based kidney care through Interwell Health and specialized pharmacy services through FreseniusRx.

Product overview

Fresenius Medical Care offers a comprehensive, multi-category product portfolio spanning in-center dialysis, home dialysis, critical care, and digital health. The core hardware portfolio includes the 5008X CAREsystem (FDA-cleared for high-volume hemodiafiltration, undergoing U.S. commercialization), the 6008 CAREsystem and 5008S CorDiax for in-center hemodialysis/HDF, the NxStage VersiHD and System One for home hemodialysis, the multiFiltratePRO critical care device for CKRT and multi-organ support, and FX-series dialyzers. The kinexus digital platform unifies peritoneal dialysis and home hemodialysis management with remote monitoring and supply ordering, built on the Huma Cloud Platform. Supporting digital tools include Therapy Data Management System (TDMS), Therapy Monitor (TMon), Nephrologic Cockpit, Body Composition Monitor, PatientOnLine, and kinexus PD. Critical care consumables include Ci-Ca Dialysate, Ultraflux AV/EMiC 2 CKRT filters, plasmaFlux plasma filters, and distributed products (CytoSorb adsorbers, multiECCO2R, proVencare catheters). The Ready4 multiFiltratePRO AR provides augmented reality training. Water technology solutions cover the complete dialysis water treatment chain.

Differentiator

Problem solved

Functional benefit

Brands

• kinexus: Unified digital platform supporting home dialysis programs, combining peritoneal dialysis and home hemodialysis management
• 5008X CAREsystem
• Interwell Health
• Renal Research Institute (RRI)
• Frenova

Products and services

• Dialysis Services (In-Center and Home Dialysis) Operation of a global network of approximately 3,539-3,600 owned dialysis clinics providing in-center and home dialysis treatments (hemodialysis and peritoneal dialysis) to approximately 290,000 patients. Services are reimbursed through Medicare, Medicaid, and private insurers, and represent the company's largest revenue stream.
• 5008X CAREsystem FDA 510(k)-cleared hemodialysis system that delivers high-volume hemodiafiltration (HDF) therapy, associated with lower three-year mortality risk compared to conventional hemodialysis. Currently available in approximately 100 U.S. clinics with more than 100,000 treatments performed as of Q1 2026.
• 6008 CAREsystem In-center hemodialysis machine designed as a modular therapy platform supporting conventional hemodialysis and online hemodiafiltration therapies for hospital and clinic use.
• 5008S CorDiax Hemodialysis machine optimized for hemodiafiltration therapy, available for both in-center and home hemodialysis use.
• 4008 series hemodialysis machines Standard hemodialysis machine series for in-center dialysis treatment in hospitals and clinics.
• FX Dialyzers (FX CorDiax, FX classix) Hollow fiber dialyzers for hemodialysis and hemodiafiltration, including the FX CorDiax line optimized for high-volume HDF and the FX classix line for standard hemodialysis.
• NxStage VersiHD Home hemodialysis system designed for flexible, daily home-based dialysis treatment, allowing patients to manage their own therapy at home.
• NxStage System One Portable home hemodialysis system enabling patients to perform dialysis independently at home.
• multiFiltratePRO Multi-modality critical care device for continuous kidney replacement therapy (CKRT) in ICU settings, supporting CKRT, Ci-Ca regional citrate anticoagulation, therapeutic plasma exchange, adsorber combination therapies, and low-flow extracorporeal CO2 removal (ECCO2R). Features built-in HL7 connectivity for PDMS integration.
• CKRT Filters and Plasma Filters (Ultraflux AV series, Ultraflux EMiC 2, plasmaFlux) Continuous kidney replacement therapy filters including Ultraflux AV filters (AV 400S, AV 600S, AV 1000S) with Fresenius Polysulfone membrane, Ultraflux EMiC 2 high-permeability membrane for middle molecule removal, and plasmaFlux plasma filters for therapeutic plasma exchange.
• Ci-Ca Dialysate (Ci-Ca Dialysate K2, Ci-Ca Dialysate K4) Dialysate solutions for Ci-Ca regional citrate anticoagulation therapy in CKRT, available in different potassium concentrations and with or without phosphate to tailor therapy to patient needs.
• CytoSorb (distributed) Extracorporeal hemoperfusion adsorber distributed by Fresenius Medical Care in selected countries (Czech Republic, Finland, France) for cytokine removal in critical care applications. Legal manufacturer: CytoSorbents Corporation, USA.
• multiECCO2R (distributed) Low-flow extracorporeal CO2 removal device distributed by Fresenius Medical Care in selected countries. Legal manufacturer: EUROSETS S.r.l., Italy. Used in combination with multiFiltratePRO or multiFiltrate for integrated CO2 removal and CKRT.
• proVencare Catheter Sets (distributed) High-flow double and triple lumen catheter sets for vascular access in critical care. Legal manufacturer: Joline GmbH & Co. KG, Germany. Distributed by Fresenius Medical Care in selected countries.
• Water Technology Solutions Complete water treatment solutions for dialysis including dialysis water supply systems, concentrate supply, and media supply to ensure water quality meets regulatory standards for hemodialysis.
• BCM - Body Composition Monitor Bioimpedance-based body composition monitoring device for assessing hydration status and fluid management in dialysis patients.
• Therapy Chairs, Beds & Medical Scales Patient seating, therapy beds, and medical scales designed for dialysis care settings to support patient comfort and clinical weighing needs.
• Ready4 multiFiltratePRO AR Augmented reality (AR) training and education application for multiFiltratePRO users, providing immersive, self-guided training for device setup, troubleshooting, and ongoing education. Runs on Microsoft HoloLens with Windows Holographic OS.
• kinexus Unified digital platform for home dialysis that combines peritoneal dialysis and home hemodialysis management within a single system. Built on the Huma Cloud Platform, it enables remote therapy monitoring, prescription management, and integrated supply ordering. Huma Therapeutics serves as legal manufacturer and Fresenius Medical Care Deutschland GmbH serves as authorized distributor.
• Interwell Health (Value-Based Kidney Care) Value-based care operating segment participating in the CMS Kidney Care Choices Model, generating revenue through shared savings arrangements with CMS. Delivered $273 million in shared savings to CMS over three years with an 88% average quality score.
• FreseniusRx (Kidney Pharmacy Services) Specialized kidney pharmacy services providing medications to dialysis patients, with studies showing reduced mortality and hospitalizations for patients using the specialized pharmacy program versus retail pharmacies.

Quantifiable outcome

• 27% increase in operating income (to EUR 2,212 million) in 2025, reaching upper end of financial outlook
• +5 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability15 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core, minor and strategic.

• Huma Therapeutics LimitedcoreTechnology or Integration · 3 June 2026Fresenius Medical Care partnered with Huma Therapeutics to build kinexus, a unified digital platform for home dialysis, on the Huma Cloud Platform. Huma serves as the digital health platform partner and legal manufacturer of kinexus. Fresenius Medical Care Deutschland GmbH is the authorized distributor. The platform combines peritoneal dialysis and home hemodialysis management within a single system.
• Humacyte Inc.minorChannel Partner/ Reseller/ Distributor · 24 April 2026Fresenius Medical Care previously held ex-U.S. distribution rights to Humacyte's Symvess bioengineered tissue product. Under an amended agreement (April 2026), Humacyte regained exclusive ex-U.S. distribution rights, with Fresenius receiving low-single-digit royalties on ex-U.S. net sales. U.S. distribution terms remain unchanged.
• Quest DiagnosticscoreStrategic or Co-development Partner · 21 April 2026Fresenius Medical Care entered a clinical testing partnership with Quest Diagnostics, contributing approximately 7% of Quest's organic volume growth in Q1 2026. Quest acquired select Fresenius clinical testing assets (Spectra Laboratories) as part of the arrangement. The collaboration expanded Quest's diagnostics footprint while providing Fresenius with diagnostic information services.
• NephronomicsstrategicStrategic or Co-development Partner · 21 April 2026Nephronomics is a joint venture between Mechanica Partners and Fresenius Medical Care focused on AI-driven kidney disease drug discovery. It claims exclusive access to what it describes as the world's largest renal dataset spanning more than 42,000 consented patients across U.S. dialysis clinics. CerraCap Ventures invested in Nephronomics to advance its machine learning platform.
• Renal Research Institute (RRI)coreStrategic or Co-development Partner · 30 October 2025Fresenius Medical Care's Renal Research Institute conducts AI-driven and real-world evidence research on dialysis outcomes, including HDF therapy benefits, patient fall risk prediction, and dietary planning tools. RRI is the company's internal research arm.
• Interwell Health (value-based care segment)coreStrategic or Co-development Partner · 1 August 2025Interwell Health is the value-based care operating segment of Fresenius Medical Care, participating in the CMS Kidney Care Choices Model. It delivered $273 million in shared savings to CMS over three years with an 88% average quality score. Fresenius increased its ownership stake in Interwell Health in September 2025.
• AzentastrategicStrategic or Co-development Partner · 1 July 2025Azenta partnered with Fresenius Medical Care and Nephronomics for genomic sequencing as part of the Nephronomics AI-driven kidney disease research initiative.

Scale indicators14 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Satellite Healthcare: Satellite Healthcare is a U.S. non-profit dialysis provider operating outpatient clinics and a significant home dialysis program. It is comparable to Fresenius Medical Care in operating model (clinic-based ESRD care) and growing emphasis on home and value-based kidney care.
• Diaverum: Diaverum is a global dialysis services provider operating clinics across Europe, the Middle East, Latin America, and Asia, directly comparable to Fresenius's international dialysis services footprint. It competes with Fresenius in many of the same emerging and developed markets outside the U.S.
• DaVita Inc. DaVita is Fresenius Medical Care's largest direct competitor in U.S. dialysis services, operating a similarly scaled network of outpatient dialysis clinics serving ESRD patients. Both companies compete head-to-head on clinic footprint, value-based care contracts, and home dialysis programs, making DaVita the closest publicly traded comparable.
• U.S. Renal Care: U.S. Renal Care is the third-largest U.S. dialysis services provider, operating outpatient clinics serving ESRD patients across multiple states. It is a direct competitor to Fresenius Medical Care's U.S. clinic network for both in-center and home dialysis patients.

Broad incumbents

• B. Braun Avitum: B. Braun's Avitum division produces hemodialysis machines, dialyzers, and operates dialysis services in select European markets, overlapping with Fresenius's device and service offerings. It is a broad medical device incumbent with renal as a strategic vertical.
• Asahi Kasei Medical: Asahi Kasei Medical manufactures hollow-fiber dialyzers and plasma fractionation products, directly competing with Fresenius's FX dialyzer portfolio. It is a broad diversified chemicals and medical device incumbent with renal therapies as a key specialty.
• Baxter International: Baxter manufactures peritoneal dialysis solutions, dialyzers, and other renal care products, directly overlapping with Fresenius's PD fluids and dialyzer portfolio. It is a broad medical products incumbent with renal as one segment among many therapy areas.
• Nipro Corporation: Nipro is a Japanese medical device manufacturer producing hollow-fiber dialyzers and dialysis equipment, directly competing with Fresenius's FX dialyzer line in Asia and other markets. It is a broad medical device incumbent with dialysis as one product category.

Emerging players

• Outset Medical: Outset Medical develops the Tablo home and in-center hemodialysis system, directly competing with Fresenius's NxStage home hemodialysis machines. As a focused pure-play in home dialysis technology, it is an emerging competitive threat to Fresenius's home dialysis franchise.
• Dialyze Direct: Dialyze Direct focuses on in-facility hemodialysis for patients in skilled nursing facilities (SNFs), an adjacent but differentiated segment of the ESRD market. It competes for a subset of Fresenius's patient population, particularly elderly and institutionalized dialysis patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/fmc_ag
• YouTubeyoutube.com/user/freseniusmedicare
• Facebookfacebook.com/freseniusmedicalcare.corporate
• LinkedInlinkedin.com/company/freseniusmedicalcare

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries5 records

Funding overview

Funding rounds30 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A15 records

Investments20 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fresenius Medical Care